Intravitreal Ziv-Aflibercept: A Comprehensive Review

ABSTRACT

Background: Age-related macular degeneration is the leading cause of blindness in adults over the age of 50 in the United States of America. Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab. Ziv-aflibercept is an analogue of aflibercept, containing the same active molecule in a different buffer solution, and its recent availability has prompted numerous pre-clinical and clinical trials addressing its viability for intraocular use, summarized herein.

Results: Trial outcomes demonstrate that ziv-aflibercept has a similar safety profile to other indicated drugs with effective maintenance or improvement of best-corrected visual acuity (BCVA) and reduction of retinal fluid or central foveal thickness (CFT). Clinical trials of ziv-aflibercept in other neovascular disorders such as diabetic macular edema (DME) and retinal vein occlusion (RVO) have shown similar results.

Conclusion: Further prospective, randomized studies of ziv-aflibercept are needed, particularly in eyes with nAMD.

Keywords:

• AMD
• anti-vascular endothelial growth factor
• diabetic macular edema
• neovascular age-related macular degeneration
• Zaltrap
• ziv-aflibercept

Disclosure of Interest

The authors report no conflict of interest.